Joseph Ross, MD, MHS
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)Cards
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
About
Copy Link
Titles
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)
Biography
Joseph S. Ross, MD, MHS, is a Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management), a member of the Center for Outcomes Research and Evaluation (CORE) at the Yale-New Haven Hospital, and an Co-Director of the National Clinician Scholars program (NCSP) at Yale. He completed his undergraduate degrees in biological science: neuroscience and psychology at the University of Rochester and his medical degree at the Albert Einstein College of Medicine, Bronx, NY. After completing his post-graduate training in primary care internal medicine at Montefiore Medical Center in Bronx, NY, Dr. Ross was a fellow in the Robert Wood Johnson Foundation Clinical Scholars program at Yale, earning a Master’s degree in health sciences research. Using health services research methods, Dr. Ross’s research focuses on examining factors which affect the use or delivery of recommended ambulatory care services for older adults and other vulnerable populations, evaluating the impact of state and federal policies on the delivery of appropriate and higher quality care, and addressing issues related to pharmaceutical and medical device regulation, evidence development, postmarket surveillance, and clinical adoption. In addition, he collaborates with a multi-disciplinary team of investigators under contract for the Centers for Medicare and Medicaid Services to develop statistical models that are used to measure and publicly report hospital and ambulatory care clinical outcomes using administrative data. Dr. Ross co-directs the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI), the Yale Open Data Access (YODA) Project, the Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) at Yale Law School, and leads efforts at Yale-New Haven Health System in collaboration with the National Evaluation System for health Technology. Dr. Ross is currently a Deputy Editor at JAMA, co-founder of medRxiv, Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), and a member of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) for ICER.
Appointments
General Internal Medicine
ProfessorPrimaryHealth Policy & Management
ProfessorSecondaryInstitution for Social and Policy Studies
ProfessorSecondary
Other Departments & Organizations
- Cancer Prevention and Control
- Center for Outcomes Research & Evaluation (CORE)
- Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT)
- General Internal Medicine
- Health Policy & Management
- Institution for Social and Policy Studies
- Internal Medicine
- National Clinician Scholars Program
- Regulatory Affairs Track
- Yale New Haven Health System
- Yale School of Public Health
- Yale Ventures
Education & Training
- MHS
- Yale School of Medicine (2006)
- Postgraduate Training
- Montefiore Medical Center (2004)
- MD
- Albert Einstein College of Medicine (2001)
- BS
- University of Rochester (1996)
- BA
- University of Rochester (1996)
Research
Copy Link
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0002-9218-3320
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Reshma Ramachandran, MD, MPP, MHS
Jeph Herrin, PhD
Jennifer E Miller, PhD
Jeptha Curtis, MD
Erica Spatz, MD, MHS
Quality of Health Care
Delivery of Health Care
Health Services Research
Publications
2026
Online Prescribing of GLP-1 Receptor Agonists.
Chetty AK, Chen AS, Ross JS, Ramachandran R. Online Prescribing of GLP-1 Receptor Agonists. JAMA 2026 PMID: 42406378, DOI: 10.1001/jama.2026.9131.Peer-Reviewed Original ResearchGrowth in Hospital-Led Payer Integration: Improving Care or Consolidating Markets?
Yu J, Ross J. Growth in Hospital-Led Payer Integration: Improving Care or Consolidating Markets? JAMA: The Journal Of The American Medical Association 2026, 335: 2113. PMID: 42207624, DOI: 10.1001/jama.2026.8645.Peer-Reviewed Original ResearchAltmetricCommercial Price Variation for Common Dermatologic Procedures.
Deitelzweig C, Dhawan R, King K, Skydel J, Ramachandran R, Ross J, Yeung H, Wallach J. Commercial Price Variation for Common Dermatologic Procedures. JAMA Dermatology 2026 PMID: 42307923, PMCID: PMC13276662, DOI: 10.1001/jamadermatol.2026.1585.Peer-Reviewed Original ResearchAltmetricComparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes
Neumiller J, Deng Y, Swarna K, Polley E, Herrin J, Galindo R, Umpierrez G, Ross J, Mickelson M, Dryden K, Tuttle K, McCoy R. Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. American Journal Of Kidney Diseases 2026 PMID: 42302979, DOI: 10.1053/j.ajkd.2026.04.007.Peer-Reviewed Original ResearchAltmetricConceptsGlucagon-like peptide-1 receptor agonistsKidney composite outcomeGlucagon-like peptide-1Chronic kidney diseaseModerate cardiovascular riskGLP-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsAssociated with reduced riskInverse probability of treatment weightingReceptor agonistsType 2 diabetesPeptidase-4 inhibitorsKidney outcomesComposite outcomeCardiovascular riskEffects of GLP-1 receptor agonistsPrimary outcomeKidney diseaseChronic kidney disease stage 3Low riskPeptide-1Associated with reduced risks of deathPeptide-1 receptor agonistsDeaths related to treatmentClass effectStrategies for enhancing participation of underrepresented patient populations in cancer clinical trials: learning from “bright spots”
Miller J, Schwartz J, Ramachandran R, Ross J, Suttiratana S. Strategies for enhancing participation of underrepresented patient populations in cancer clinical trials: learning from “bright spots”. BMC Cancer 2026 PMID: 42288829, DOI: 10.1186/s12885-026-16181-1.Peer-Reviewed Original ResearchConceptsCancer clinical trialsClinical trialsPatient populationFDA approvalSpot trialsCancer clinical researchClinician engagementResultsThirteen participantsReferral trainingParticipation barriersPerformance-based incentivesOlder adultsCommunity partnershipsTrial teamLatinx patientsSite burdenNovel cancer therapeuticsEnrollment goalsEthnic subgroupsEligibility criteriaDisease burdenEducation programsReal-time dashboardTrial eligibilityLeadership commitmentInternet Searches for Leucovorin, Folate, and Acetaminophen After a White House Autism Announcement
Patel N, Ramachandran R, Ross J. Internet Searches for Leucovorin, Folate, and Acetaminophen After a White House Autism Announcement. JAMA Network Open 2026, 9: e2617910. PMID: 42275066, PMCID: PMC13261488, DOI: 10.1001/jamanetworkopen.2026.17910.Peer-Reviewed Original ResearchCitationsAltmetricEconomic and Resource Use–Related Guidance in US Medical Societies’ Clinical Practice Guidelines
Habib A, Qureshi O, Ramachandran R, Ross J. Economic and Resource Use–Related Guidance in US Medical Societies’ Clinical Practice Guidelines. JAMA Network Open 2026, 9: e2620297. PMID: 42360742, PMCID: PMC13309863, DOI: 10.1001/jamanetworkopen.2026.20297.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClinical practice guidelinesValue-based careCross-sectional studyClinical practice guideline documentOdds ratioPractice guidelinesPrimary care societiesMedical societiesHealth economic evidenceMultilevel multivariate analysesCPG recommendationsMain OutcomesEconomic evidenceNarrative discussionCare SocietyMultisocietyCareMethodical manualsDiagnostic-relatedSummary StatementRecommendationsTreatment-relatedMultivariate analysisGuidelinesOddsOrphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
Costa E, Ross J, Kesselheim A. Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis. Clinical Pharmacology & Therapeutics 2026 PMID: 42218735, DOI: 10.1002/cpt.70349.Peer-Reviewed Original ResearchConceptsOrphan drug designationEuropean UnionEuropean Medicines AgencyUnited StatesDrug approvalFood and Drug AdministrationRegulatory frameworkMarket exclusivityApplication feesOrphan designationRare disease drugsEU designEuropeanPediatric indicationsDrug designAgenciesUnionMedicines AgencyApprovalEuropean Medicines Agency approvalSubsets of cancersGenetic diseasesStateIncentivesCross-sectional studyCommercial price variation in precision oncology testing across US hospitals.
Mooghali M, Skydel J, Gross C, Walther Z, Lustberg M, Dusetzina S, Ross J, Wallach J. Commercial price variation in precision oncology testing across US hospitals. Journal Of Clinical Oncology 2026, 44: 11062-11062. DOI: 10.1200/jco.2026.44.16_suppl.11062.Peer-Reviewed Original ResearchConceptsPercentage of hospitalsCross-sectional analysisPrecision oncology testingUS hospitalsShort-term acute care hospitalsCancer care costsPatient out-of-pocket costsAcute care hospitalsBetween-hospital variationClinical Laboratory Fee ScheduleOut-of-pocket costsLaboratory Fee ScheduleBiomarker testingOncology testingCancer careCare accessClinical decision-makingPrice variationHealth databasesCare costsOncotype DX Breast Recurrence ScoreClinical guidelinesCare hospitalProcedural Terminology codesPayersClinical Evidence Supporting US Food and Drug Administration Approval of Original and Supplemental New Dermatologic Indications, 2014-2023
Kamat S, Ungar B, O'Hagan R, Wan J, Ross J, Gupta R. Clinical Evidence Supporting US Food and Drug Administration Approval of Original and Supplemental New Dermatologic Indications, 2014-2023. Journal Of The American Academy Of Dermatology 2026 PMID: 42176707, DOI: 10.1016/j.jaad.2026.05.047.Peer-Reviewed Original ResearchConcepts
Academic Achievements & Community Involvement
Copy Link
Activities
activity JAMA
06/01/2023 - PresentJournal ServiceDeputy Editoractivity BMJ
2020 - 2023Journal ServiceAssociate Editoractivity JAMA Internal Medicine
04/01/2013 - 12/31/2019Journal ServiceAssociate Editoractivity Journal of General Internal Medicine
2011 - 2013Journal ServiceDeputy Editor
News
Copy Link
News
- July 07, 2026
An Online Secret Shopping Study Reveals Easy Access to GLP-1 Prescriptions with Limited Clinician Oversight
- March 05, 2026Source: Yale News
Cost of Physical Therapy Varies Widely from State-to-State
- November 03, 2025Source: JAMA
Dean Megan Ranney contributes to new report aimed at reducing firearm violence
- October 21, 2025Source: Yale News
IV Hydration Spas Lack Adequate Oversight, Study Finds
Get In Touch
Copy Link
Contacts
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Ste 405B
New Haven, CT 06510